Table 1 Patient characteristics (n=99)

From: Assessment of residual tumour by FDG-PET: conventional imaging and clinical examination following primary chemotherapy of large and locally advanced breast cancer

Age (years)

 Median

50

 Range

30–66

Menopausal status (n)

 Premenopausal

49

 Postmenopausal

50

cT before chemotherapy (n)

 T2

39

 T3

42

 T4

15

 Tx

3

cN before chemotherapy (n)

 N0

22

 N1

56

 N2

11

 Nx

10

Estrogen receptor status (n)

 Positive

61

 Negative

32

 Not available

6

Histology (n)

 Invasive ductal

87

 Invasive lobular

11

 Invasive medullary

1

Grading (n)

 G2

52

 G3

45

 Not available

2

Chemotherapy (n)

 ET regimen

55

 EP regimen

44

Residual disease after chemotherapy (n)

 Minimal residual disease

17

 Gross residual disease

82

  1. Abbreviations: ET regimen=epirubicin and paclitaxel; cT=clinical tumour stage according to TNM classification; cN=clinical lymph node status according to TNM classification; EP=3 cycles epirubicin followed by 3 cycles paclitaxel at intervals of 2 weeks; ET=4 cycles of combined epirubicin plus paclitaxel at intervals of 3 weeks.
Back to article page